Probenecid as a pharmacotherapy for alcohol use disorder: A randomized placebo-controlled alcohol interaction trial.
Rivkah Hornbacher, Brian J Gully, Zoe E Brown...
https://pubmed.ncbi.nlm.nih.gov/39472130/Actively Recruiting
Led by Brown University · Updated on 2026-03-17
120
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of the drug probenecid on alcohol craving and consumption in adults with Alcohol Use Disorder AUD. This Phase 2, double-blind, randomized controlled trial aims to test whether taking 2 grams of probenecid daily can reduce both acute and naturalistic alcohol craving, as well as actual alcohol consumption. The study is sponsored by Brown University and focuses on individuals with moderate to severe AUD as defined by DSM-5 criteria. The study compares two groups one receiving oral probenecid tablets 2 grams daily and the other receiving inactive placebo tablets. The trial lasts 16 weeks and includes a laboratory phase to measure acute craving and a naturalistic phase to monitor craving and drinking in real-world settings. Participants will be randomly assigned to either the probenecid or placebo group, and both participants and researchers are blinded to which treatment is given. Participants will visit the study site regularly for assessments including breath alcohol content tests, questionnaires, medical exams, and lab tests. The primary outcome is the level of acute alcohol craving over 5 weeks, with a secondary outcome measuring craving over 12 weeks. The study monitors health status and adherence to procedures throughout. Total participation spans the 16-week trial period and includes safety checks and outcome evaluations.
CONDITIONS
Probenecid Administration for Alcohol Craving and Consumption
B
Brian Gully, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brown University
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Probenecid Oral Tablet | Placebo Oral Tablet |
|---|---|---|
| What it is | A prescription oral medication (probenecid) studied for potential effects on alcohol craving and consumption in people with moderate to severe Alcohol Use Disorder. | An inactive (placebo) tablet designed to match the probenecid tablet, containing no active medication. |
| Role in the trial | Participants in this arm receive probenecid to test its effects on reducing alcohol craving and use. | Participants receive an identical-looking placebo tablet to compare outcomes against the probenecid group. |
| Primary use | Being studied for its ability to reduce craving and consumption in adults with moderate to severe Alcohol Use Disorder—this use is investigational. | Does not contain active medication; used as a comparator to test the effects of probenecid. |
| How it is given or performed | Given as a 2-gram oral tablet daily. | Placebo oral tablet taken daily in the same manner as the probenecid tablet. |
| Evidence status | Probenecid is being evaluated for its potential effects on alcohol craving and use; results for this indication are not yet established. Initial safety and pharmacokinetic data in adults with Alcohol Use Disorder have been published. | Placebo contains no active drug; serves as a comparator to determine if changes in craving are due to probenecid. |
| Important limitations | Evidence for the use of probenecid in reducing alcohol craving is preliminary, with main efficacy outcomes from this trial not yet reported. Long-term effects and safety in this specific use remain unproven. | Placebo does not offer therapeutic benefit for alcohol craving, but is used to control for psychological and expectation effects in clinical trials. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive daily oral tablets of either Probenecid or placebo to evaluate effects on alcohol craving and consumption.
Weekly visits for up to 12 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rivkah Hornbacher, Brian J Gully, Zoe E Brown...
https://pubmed.ncbi.nlm.nih.gov/39472130/Brown University
Lead Sponsor